Fig. 2
From: Targeting MYH9 represses USP14-mediated NAP1L1 deubiquitination and cell proliferation in glioma
MYH9 enhances cell proliferation and resistance to temozolomide. (A, B) MYH9 expression was measured by RT-PCR assays and western blot in U87 and LN229 cells transfected with shNC ,shMYH9-1 and shMYH9-2. GAPDH was used as a loading control. (C) MYH9 protein level was measured by western blot in U87 and LN229 cells transfected with siNC or siMYH9. GAPDH was used as a loading control. CCK8 assay (D), EdU incorporation assay (E), clone formation assay (F) after MYH9 knockdown. (G) Dose-response curves of U87 and LN229 treated with siMYH9 and siNC respectively following treatment with temazolamide for 48 h. Data are presented as the mean ± SD for three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001